PROTAC targeted protein degraders: the past is prologue
2022 · Nature Reviews Drug Discovery · 2,731 citations
https://doi.org/10.1038/s41573-021-00371-6
D
David R. Langley
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
138
Papers
8.5K
Citations
43
h-index
79
i10-index
David R. Langley is an academic researcher from Arvinas (United States). The author has contributed to research in topics: HIV/AIDS drug development and treatment & HIV Research and Treatment & Protein Structure and Dynamics. The author has an h-index of 43, co-authored 118 publications.
ORCID: 0000-0002-0820-3190Papers by this author
worksOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
2024 · Clinical Cancer Research · 132 citations
https://doi.org/10.1158/1078-0432.ccr-23-3465
5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases
2007 · Bioorganic & Medicinal Chemistry Letters · 30 citations
https://doi.org/10.1016/j.bmcl.2007.06.019
Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases
2007 · Bioorganic & Medicinal Chemistry Letters · 28 citations
https://doi.org/10.1016/j.bmcl.2007.02.050
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat